D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 85 Citations 26,411 244 World Ranking 7681 National Ranking 4187

Research.com Recognitions

Awards & Achievements

1996 - Fellow of the American Association for the Advancement of Science (AAAS)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Chemotherapy

His primary areas of investigation include Internal medicine, Gastroenterology, Leukemia, Chemotherapy and Surgery. His work in Internal medicine is not limited to one particular discipline; it also encompasses Oncology. Emil J. Freireich has researched Gastroenterology in several fields, including Granulocyte colony-stimulating factor, Pneumonia, Dexamethasone, Blood transfusion and Toxicity.

His studies in Leukemia integrate themes in fields like Myeloid and Myeloid leukemia. His Chemotherapy research is multidisciplinary, relying on both Hairy cell leukemia, Incidence and Confidence interval. His study in Acute leukemia is interdisciplinary in nature, drawing from both Mercaptopurine, Methotrexate, MEDLINE and Bone marrow, Pathology.

His most cited work include:

  • Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia (2050 citations)
  • Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. (1294 citations)
  • Flow Cytometry in Clinical Cancer Research (694 citations)

What are the main themes of his work throughout his whole career to date?

Emil J. Freireich spends much of his time researching Internal medicine, Leukemia, Immunology, Acute leukemia and Gastroenterology. The concepts of his Internal medicine study are interwoven with issues in Surgery and Oncology. His work carried out in the field of Leukemia brings together such families of science as Myeloid, Myeloid leukemia and Bone marrow, Pathology.

In his research on the topic of Pathology, Karyotype is strongly related with Cytogenetics. His studies deal with areas such as Combination chemotherapy and Acute lymphocytic leukemia as well as Acute leukemia. His research in Gastroenterology tackles topics such as Vincristine which are related to areas like Prednisone.

He most often published in these fields:

  • Internal medicine (47.65%)
  • Leukemia (36.38%)
  • Immunology (26.06%)

What were the highlights of his more recent work (between 2001-2020)?

  • Internal medicine (47.65%)
  • Leukemia (36.38%)
  • Immunology (26.06%)

In recent papers he was focusing on the following fields of study:

Emil J. Freireich mainly focuses on Internal medicine, Leukemia, Immunology, Myeloid leukemia and Surgery. His Internal medicine research includes themes of Gastroenterology and Oncology. His Gastroenterology research includes elements of Regimen, Cyclophosphamide, Fludarabine, Acute lymphocytic leukemia and Acute leukemia.

His Leukemia research is multidisciplinary, incorporating elements of Myeloid, Cancer research, Imatinib mesylate, Survival rate and Intensive care medicine. His research in Myeloid leukemia focuses on subjects like Acute promyelocytic leukemia, which are connected to Arsenic trioxide, Multiple myeloma and Toxicity. His Surgery research is multidisciplinary, incorporating perspectives in Blastic Phase and Myelodysplastic syndromes.

Between 2001 and 2020, his most popular works were:

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia (432 citations)
  • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. (371 citations)
  • Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia (296 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Chemotherapy

Emil J. Freireich focuses on Internal medicine, Leukemia, Myeloid leukemia, Surgery and Oncology. His Internal medicine research incorporates elements of Gastroenterology and Immunology. The Leukemia study combines topics in areas such as Myeloid, Bone marrow, Acute promyelocytic leukemia and Intensive care medicine.

His Myeloid leukemia study integrates concerns from other disciplines, such as Preleukemia, Chemotherapy regimen and Acute leukemia. Within one scientific family, Emil J. Freireich focuses on topics pertaining to Myelodysplastic syndromes under Surgery, and may sometimes address concerns connected to Risk factor. Emil J. Freireich has included themes like Cancer, Haematopoiesis and Chronic lymphocytic leukemia in his Oncology study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

Gerald P. Bodey;Monica Buckley;Y. S. Sathe;Emil J Freireich.
Annals of Internal Medicine (1966)

3364 Citations

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Freireich Ej;Gehan Ea;Rall Dp;Schmidt Lh.
Cancer chemotherapy reports (1966)

2033 Citations

Flow Cytometry in Clinical Cancer Research

Barthel Barlogie;Martin N. Raber;Johannes Schumann;Tod S. Johnson.
Cancer Research (1983)

1072 Citations

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

Sewa S. Legha;Robert S. Benjamin;Bruce Mackay;Michael Ewer.
Annals of Internal Medicine (1982)

1013 Citations

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel.
Blood (2000)

976 Citations

Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

Susan M. O’Brien;Hagop Kantarjian;Deborah A. Thomas;Francis J. Giles.
Journal of Clinical Oncology (2001)

741 Citations

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

M. J. Keating;Hagop M Kantarjian;M. Talpaz;J. Redman.
Blood (1989)

695 Citations

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes.
Cancer (2004)

658 Citations

The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.

Lawrence A. Gaydos;Emil J. Freireich;Nathan Mantel.
The New England Journal of Medicine (1962)

656 Citations

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.

M. J. Keating;S. O'Brien;S. Lerner;C. Koller.
Blood (1998)

635 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Emil J. Freireich

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 550

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 312

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 295

Michael J. Keating

Michael J. Keating

The University of Texas MD Anderson Cancer Center

Publications: 222

Elihu H. Estey

Elihu H. Estey

Fred Hutchinson Cancer Research Center

Publications: 188

Guillermo Garcia-Manero

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

Publications: 182

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 159

Francis J. Giles

Francis J. Giles

National University of Ireland, Galway

Publications: 154

Gerald P. Bodey

Gerald P. Bodey

The University of Texas MD Anderson Cancer Center

Publications: 142

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 138

Stefan Faderl

Stefan Faderl

The University of Texas MD Anderson Cancer Center

Publications: 128

Sherry Pierce

Sherry Pierce

The University of Texas MD Anderson Cancer Center

Publications: 106

William G. Wierda

William G. Wierda

The University of Texas MD Anderson Cancer Center

Publications: 102

Moshe Talpaz

Moshe Talpaz

University of Michigan–Ann Arbor

Publications: 101

William Plunkett

William Plunkett

The University of Texas MD Anderson Cancer Center

Publications: 100

Zeev Estrov

Zeev Estrov

The University of Texas MD Anderson Cancer Center

Publications: 98

Something went wrong. Please try again later.